| 1 |
International Agency for Research on Cancer. Global cancer observatory: cancer today [EB/OL]. [2021-01-11].
URL
|
| 2 |
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019版) [J]. 中国癌症杂志, 2019, 29(8): 609-680.
|
| 3 |
Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005, 55(2): 74-108.
|
| 4 |
Trudeau M, Sinclair SE, Clemons M, et al. Neoadjuvant taxanes in the treatment of non-metastatic breast cancer: a systematic review [J]. Cancer Treat Rev, 2005, 31(4): 283-302.
|
| 5 |
Hammond ME, Hayes DF, Wolff AC, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer [J]. J Oncol Pract, 2010, 6(4): 195-197.
|
| 6 |
Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update [J]. Arch Pathol Lab Med, 2014, 138(2): 241-256.
|
| 7 |
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2013 [J]. Ann Oncol, 2013, 24(9): 2206-2223.
|
| 8 |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
|
| 9 |
Kinsella MD, Nassar A, Siddiqui MT, et al. Estrogen receptor (ER), progesterone receptor (PR), and HER-2 expression pre- and post-neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience [J]. Int J Clin Exp Pathol, 2012, 5(6): 530-536.
|
| 10 |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
|
| 11 |
Early Breast Cancer Trialists′ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials [J]. Lancet Oncol, 2018, 19(1): 27-39.
|
| 12 |
DeMichele A, Yee D, Esserman L. Mechanisms of resistance to neoadjuvant chemotherapy in breast cancer [J]. N Engl J Med, 2017, 377(23): 2287-2289.
|
| 13 |
Rossi L, Verrico M, Tomao S, et al. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy [J]. Cancer Chemother Pharmacol, 2020, 85(1): 105-111.
|
| 14 |
Chou HH, Kuo WL, Yu CC, et al. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy [J]. Biomed J, 2019, 42(1): 66-74.
|
| 15 |
Haque W, Verma V, Hatch S, et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy [J]. Breast Cancer Res Treat, 2018, 170(3): 559-567.
|
| 16 |
Derks M, Van D. Neoadjuvant chemotherapy in breast cancer: more than just downsizing [J]. Lancet Oncol, 2018, 19(1): 2-3.
|
| 17 |
Chaudhary LN, Wilkinson KH, Kong A. Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? [J]. Surg Oncol Clin N Am, 2018, 27(1): 141-153.
|
| 18 |
Masuda N, Lee SJ, Ohtani S, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy [J]. N Engl J Med, 2017, 376(22): 2147-2159.
|
| 19 |
Wang X, Wang SS, Huang H, et al. Effect of capecitabine maintenance therapy using lower dosage and higher frequency vs observation on disease-free survival among patients with early-stage triple-negative breast cancer who had received standard treatment: The SYSUCC-001 Randomized Clinical Trial [J]. JAMA, 2021, 325(1): 50-58.
|
| 20 |
Conte P, Schneeweiss A,Loibl S, et al. Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2-positive breast cancer [J]. Cancer, 2020, 126(13): 3132-3139.
|
| 21 |
Laas E, Labrosse J, Hamy AS, et al. Determination of breast cancer prognosis after neoadjuvant chemotherapy: comparison of Residual Cancer Burden (RCB) and Neo-Bioscore [J]. Br J Cancer, 2021, 124(8): 1421-1427.
|